Significant Mortality Benefit Seen With Sustained HCV Virologic Response With DAAs

Significant Mortality Benefit Seen With Sustained HCV Virologic Response With DAAs
Hannah Dellabella

For patients infected with hepatitis C virus (HCV) without advanced liver disease, achieving sustained virologic response with direct-acting antivirals (DAAs) is associated with decreased mortality, according to results published in Hepatology.

Continue reading overview of study: https://www.infectiousdiseaseadvisor.com/hepatitis-advisor/mortality-risk-decrease-with-daas-in-hepatitis-c-without-advanced-liver-disease/article/745269/